Combination chemotherapy in advanced XXXX .

@entity43 @entity1 @entity632 @entity137 @entity44209 @entity900 @entity786 @entity13324 @entity204
@entity43 is the fifth most common cause of @entity204 among @entity1 in western countries. It is often diagnosed in an advanced stage (FIGO Stage III and IV) and requires effective chemotherapy as first-line treatment. The advent of @entity900 combined with @entity632 and @entity786 has remarkably increased the response rate in advanced disease. The authors report 31 cases of @entity43 , without prior chemotherapy, treated with @entity900 , @entity632 and @entity786 (PAC I). Of the 30 evaluable @entity1 , 15 had clinical complete remissions (cCR = 50%), 10 clinical partial remissions ( @entity13324 = 33%) and 5 no response (NR = 17%). The total response (cCR + @entity13324 ) was equal to 83%. Twelve of the 15 @entity1 in cCR underwent second-look laparotomy; in 8 of these cases, histologic and cytologic confirmation of CR was obtained. @entity44209 was found to be a highly effective therapeutic regimen with moderate @entity137 . The individual @entity137 reported was gastroenteric (nausea and vomiting), but transitory. No chronic toxic side-effects from @entity900 or @entity632 were noted. However, more definitive results must be obtained to verify its impact on the prolongation of survival.
